NCT04759352

Brief Summary

The purpose of the GEO-STAR randomized non-inferiority trial is to compare the outcome of post-test telephone cancer genetic counseling with standard in-person cancer genetic counseling. We hypothesize that telephone counseling is non-inferior by outcome if compared to standard in-person counseling.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
724

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started May 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 15, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

February 18, 2021

Completed
3 months until next milestone

Study Start

First participant enrolled

May 15, 2021

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2025

Completed
Last Updated

July 28, 2021

Status Verified

July 1, 2021

Enrollment Period

4 years

First QC Date

February 15, 2021

Last Update Submit

July 22, 2021

Conditions

Keywords

genetic telecounsellingtest result communication

Outcome Measures

Primary Outcomes (3)

  • "Multidimensional Impact of Cancer Risk Assessment" questionnaire

    Impact of post-test counseling on patients. The "Multidimensional Impact of Cancer Risk Assessment" questionnaire measures distress, uncertainty and positive experiences associated to cancer genetic testing. A version adapted to the Italian context will be used, where a single item related to insurance has been removed because not applicable to the Italian Health System. The resulting possible scores range from 0 to 100. Higher scores indicate more negative impacts of cancer risk assessment.

    Seven days after the post-test genetic counseling session

  • "Patient perceptions of the genetic counseling questionnaire"

    Impact of post-test counseling on patients. The range of scores is from 8 to 31. Higher scores indicate positive perception of the genetic counseling session.

    Seven days after the post-test genetic counseling session

  • "Genetic Counselor process Questionnaire"

    Professionals perceptions measured by the Genetic Counselor process Questionnaire completed by professionals who provided the post-test genetic counseling. The range of scores is from 4 to 20. Higher scores indicate positive perception of the genetic counselor.

    Immediately after the post-test genetic counseling session

Secondary Outcomes (2)

  • Influence of sociodemographic and medical history on genetic counseling outcomes

    Data collection during pre-test genetic counseling session

  • Impact of logistics on genetic counseling preferences

    Data collection during the pre-test genetic counseling session

Study Arms (2)

Telephone post-test genetic counseling

EXPERIMENTAL

Post-test genetic counseling delivered by telephone

Other: Post-test genetic counseling delivered by telephone

In-person post-test genetic counseling

NO INTERVENTION

Post-test genetic counseling delivered in-person

Interventions

Participants enrolled in the experimental arm will receive genetic counseling for test result communication by telephone.

Telephone post-test genetic counseling

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients over 18 years of age inclusive at the time of the study;
  • Patients must have undergone an in-person pre-test genetic counseling session;
  • Patients must have undertaken cancer genetic testing;
  • Patients must be able to speak Italian fluently;
  • Patients must have got an email address.

You may not qualify if:

  • Patients unable to provide informed consent, for example due to mental incapacity or active psychotic illness.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UO Genetica Medica, IRCCS AOU di Bologna

Bologna, 40138, Italy

RECRUITING

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof.

Study Record Dates

First Submitted

February 15, 2021

First Posted

February 18, 2021

Study Start

May 15, 2021

Primary Completion

April 30, 2025

Study Completion

April 30, 2025

Last Updated

July 28, 2021

Record last verified: 2021-07

Data Sharing

IPD Sharing
Will not share

Locations